The Humanistic and Economic Burden of Treatment-resistant Depression: A PHQ-9 Severity Analysis

Tony B. Amos, PharmD, MS1; Edward A. Witt, PhD2; Larry Alphs, MD, PhD1; Allitia DiBernardo, MD3; Neeta Tandon, MA1
1Janssen Scientific Affairs, LLC, Titusville, NJ; 2Kantar Health, New York, NY; 3Janssen Global Services, LLC, Titusville, NJ

OBJECTIVE

To examine the humanistic and economic burden of treatment-resistant depression (TRD) in the US adult population, using data from the 2013 US National Health and Wellness Survey (NHWS) - a contemporary, self-reported survey of US adults (aged ≥18 years).

METHODS

Data Source

Data were drawn from the 2013 NHWS, a contemporary survey of US adults (aged ≥18 years). The NHWS is one of the largest, ongoing, self-reported, health surveys conducted in the United States, and is designed to be representative of the non-institutionalized US population aged ≥18 years. Potential participants were excluded from the study if they had a personal diagnosis of HIV or AIDS, metastatic cancer, or had an emergency room visit in the last 2 weeks. In addition, patients with depression who are in remission (i.e., None to Minimal) and those patients with depression who have not responded to their first antidepressant (i.e., Likely TRD) were included in the analysis sample.

Outcome Measures

Statistical Analysis

Multivariable techniques, such as regression analysis, were used to establish the temporality or to make causal associations about the outcomes of interest. Outcome measures were compared between the Likely TRD and the None to Minimal groups using chi-square tests, whereas differences in continuous variables between groups were compared using t-tests. Statistical significance was evaluated at a 0.05 level. All analyses were performed by KHQ data management and analytics. Regression analysis was performed by Janssen Global Services, LLC, Titusville, NJ.

RESULTS

Depression-specific Measures

Table 1: Depression-specific Measures by PHQ-9 depression severity group

<table>
<thead>
<tr>
<th>Measure</th>
<th>None to Minimal</th>
<th>Likely TRD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHQ-9a</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>HADS-D</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>HADS-A</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>HAM-D</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>HAM-A</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>MRS</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>SF-6D</td>
<td>0.0%</td>
<td>2.6%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

DISCLOSURES

This research was funded by Janssen Scientific Affairs, LLC. The authors thank Janssen Global Services, LLC, Titusville, NJ, for their editorial assistance.

REFERENCES


ACKNOWLEDGMENTS

Janssen Scientific Affairs, LLC, under the direction of Dr. Tony B. Amos, submitted this abstract. The authors would like to acknowledge the contributions of all the study team members.

Poster presented at the Anxiety and Depression Association of America (ADAA) Annual Conference; April 6-9, 2017; San Francisco, California.